THX Pharma (FRA:3VG) LT-Debt-to-Total-Asset: 0.11 (As of Dec. 2025)


FRA:3VG THX Pharma FRA:3VG
30 GF Score
Price €3.22
! 1 Warning Sign
View Full Analysis

What is THX Pharma LT-Debt-to-Total-Asset?

THX Pharma FRA:3VG +1.10% 30 LT-Debt-to-Total-Asset is 0.11 as of Dec. 2025. GuruFocus rates FRA:3VG with a GF Score™ of 30/100. The stock has 1 warning sign investors should review.

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. THX Pharma's long-term debt to total assests ratio for the quarter that ended in Dec. 2025 was 0.11.

THX Pharma's long-term debt to total assets ratio declined from Dec. 2024 (0.75) to Dec. 2025 (0.11). It may suggest that THX Pharma is progressively becoming less dependent on debt to grow their business.

THX Pharma  (FRA:3VG) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

THX Pharma LT-Debt-to-Total-Asset Related Terms

THX Pharma LT-Debt-to-Total-Asset Historical Data

* Premium members only.

The historical data trend for THX Pharma's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

THX Pharma LT-Debt-to-Total-Asset Chart

THX Pharma Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
LT-Debt-to-Total-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.32 0.41 0.34 0.75 0.11

THX Pharma Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
LT-Debt-to-Total-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.34 0.69 0.75 0.57 0.11
FRA:3VG
30GF Score
THX Pharma FRA:3VG
LT-Debt-to-Total-Asset is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

THX Pharma LT-Debt-to-Total-Asset Calculation

THX Pharma's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as

LT Debt to Total Assets (A: Dec. 2025 )=Long-Term Debt & Capital Lease Obligation (A: Dec. 2025 )/Total Assets (A: Dec. 2025 )
=1.117/10.545
=

THX Pharma's Long-Term Debt to Total Asset Ratio for the quarter that ended in Dec. 2025 is calculated as

LT Debt to Total Assets (Q: Dec. 2025 )=Long-Term Debt & Capital Lease Obligation (Q: Dec. 2025 )/Total Assets (Q: Dec. 2025 )
=1.117/10.545
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about LT-Debt-to-Total-Asset →
What does a LT-Debt-to-Total-Asset of 0.11 mean?
THX Pharma (FRA:3VG) has a LT-Debt-to-Total-Asset of 0.11 as of Dec. 2025. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on THX Pharma and its competitors.
Is THX Pharma's LT-Debt-to-Total-Asset too high?
THX Pharma's current LT-Debt-to-Total-Asset is 0.11. Overall, THX Pharma has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does THX Pharma's LT-Debt-to-Total-Asset compare to VRTX and REGN?
THX Pharma's LT-Debt-to-Total-Asset of 0.11 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good LT-Debt-to-Total-Asset for a Biotechnology company?
A good LT-Debt-to-Total-Asset depends on the Biotechnology industry context. However, LT-Debt-to-Total-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high LT-Debt-to-Total-Asset mean?
A high LT-Debt-to-Total-Asset can signal that a stock is expensive relative to its fundamentals. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on THX Pharma and its competitors. THX Pharma's current LT-Debt-to-Total-Asset is 0.11. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is THX Pharma stock overvalued right now?
THX Pharma (FRA:3VG) has a current LT-Debt-to-Total-Asset of 0.11. The current LT-Debt-to-Total-Asset is 0.11. THX Pharma's overall GF Score™ is 30/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is LT-Debt-to-Total-Asset calculated?
LT-Debt-to-Total-Asset is calculated from a company's financial statements. For THX Pharma (FRA:3VG), the current LT-Debt-to-Total-Asset is 0.11 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

THX Pharma Business Description

Other Exchanges ALTHX:France3VG:Germany
Address 60 avenue Rockefeller, Pepiniere Laennec, Lyon, FRA, 69008
THX Pharma Formerly Theranexus SA is a France based biopharmaceutical company. It is engaged in developing drug candidates to be used in the treatment of central nervous system (CNS) disorders. The company's therapeutics platform is based on simultaneously targeting neurons and glial cells by creating and developing innovative combinations of two distinct drugs: a CNS drug targeting neuronal activity; and a drug targeting glial cells. The drug candidates of the organization are THN102 to treat excessive daytime sleepiness in Parkinson's disease, THN201 for the treatment of neurocognitive disorders in Alzheimer's disease and THN101 for neuropathic pain.
30GF Score

Get the complete analysis for FRA:3VG

LT-Debt-to-Total-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€3.22
Price